Anti-VEGF Market Technology
The Anti-VEGF Market is a hotbed of technological innovation, with new tools and platforms constantly emerging to accelerate drug development and improve patient care. A key technological driver is the development of longer-acting formulations. Companies are creating drugs that can be administered less frequently, reducing the burden of monthly or bimonthly injections. This includes developing new molecular entities that have a longer half-life in the eye, as well as new drug delivery systems such as sustained-release implants that can deliver the medication over several months.
Another significant technological advancement is the use of bispecific antibodies, which are designed to target and inhibit multiple disease pathways simultaneously. For example, a new drug like Vabysmo targets both VEGF and angiopoietin-2 (Ang-2), offering a more potent therapeutic effect. The market is also seeing the application of gene therapy to deliver a single, long-lasting treatment for retinal diseases, which could potentially eliminate the need for repeated injections entirely. These technological leaps are making the treatment of retinal diseases more effective, convenient, and patient-centric.